CAMBRIDGE, Mass., Aug. 1, 2024 -- Myeloid Therapeutics, Inc. ("Myeloid"), a clinical-stage immunology company advancing RNA therapeutics to conquer cancer, announced today its participation in the Barclays Biotech: 1x1 Private Company Symposium on Wednesday, August 7, 2024.
This event is being held in a virtual format during which Company management will participate in one-on-one meetings with investors.
About Myeloid Therapeutics
Myeloid Therapeutics is a clinical stage immunology company, engineering cutting-edge RNA technology to program immune cells to combat cancer and other deadly diseases. Myeloid is headquartered in Cambridge, MA.
For additional information, please visit, https://www.myeloidtx.com/ and follow us on LinkedIn and X/Twitter. For collaborative interests, write to partnering@myeloidtx.com.
Investor Contact
Amy Conrad
Juniper Point
Amy@juniper-point.com
This News is brought to you by Qube Mark, your trusted source for the latest updates and insights in marketing technology. Stay tuned for more groundbreaking innovations in the world of technology.
